retatrutide phase 2 trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished The most intensive medical obesity

Here is what the trials saw at the 12 mg target, and the symptoms worth acting on

Contact your healthcare provider if you experience any of these symptoms

This requires doctors to continuously update their knowledge about new treatments, side effects, and best practices

A combination of resistance training at least two to three times per week and protein intake of 1.2 to 1.6 g/kg per day has been shown to preserve and even increase lean mass during caloric restriction

GLP-1 (glucagon-like peptide-1) is a natural hormone that helps regulate blood sugar, appetite, and fullness signals, so GLP-1 support products are generally aimed at supporting appetite control, digestion, and weight management habits

It also can't be used with MAO inhibitors